Canada: Aegerion Pharmaceuticals And Amryt Pharma In Agreement For Lojuxta Therapy
Last Updated: September 13 2017

Gowling WLG's Life Sciences team, led by partner Patrick Duxbury and including Mathilda Davidson, Alice Stagg, James Barr and Bernardine Adkins, have assisted Aegerion Pharmaceuticals in its licensing agreement with Amryt Pharma.

Under the terms of the agreement, Amryt is granted the exclusive rights to the medical product Lojuxta hard capsules in the European Economic Area (EEA), Switzerland, Turkey and certain Middle Eastern and North African countries.

The team advised Aegerion on the complex drafting and negotiation of the transaction documents. The agreement includes an exclusive license for Amryt to promote and distribute the drug, paying Aegerion sales-related milestone payments and royalties. Amryt will also be responsible for ongoing regulatory and part-marketing obligations in support of the Lojuxta brand. 

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Gowling WLG
By Belinda Bain, Olivia Lifman
By Jason Coates, Christopher Stiles, Joanne Tibbott
By John Coldham
By Ian Mondrow
By Daniel Wood, Clark Sargent, Cathy Moore
By Helen Davenport, Jane Bates
By Paul M. Murphy
By John Coldham
By James Sidwell, Susannah Fink, Christopher Richards
Font Size: